Skip to main content
Fig. 1 | EJNMMI Research

Fig. 1

From: [68Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport

Fig. 1

The Albumod technology (schematic model). The Affibody albumin-binding domain (ABD) protein (yellow) binds to albumin (gray/white, crystal structure, PDB no: 1TF0) via a regioselective, tight interaction with domain II as earlier demonstrated by Johansson [20] and based on crystal structure by Lejon [21]. Effector molecules (red) are site-specifically attached to ABD in a position remote from the albumin binding surface. The effector molecule is thus held in circulation with a biological half-life similar to that of albumin, thereby increasing the probability that the administered effector molecule will reach (and interact) with its target. For radiodiagnostics, the effector is a radionuclide. For therapeutics, the effector may be a therapeutic radionuclide, targeting drugs, particles, or fusion proteins

Back to article page